XML 76 R56.htm IDEA: XBRL DOCUMENT v3.3.1.900
ALLIANCES (Lilly) (Details) - USD ($)
$ in Millions
3 Months Ended 12 Months Ended
Dec. 31, 2015
Sep. 30, 2015
Jun. 30, 2015
Mar. 31, 2015
Dec. 31, 2014
Sep. 30, 2014
Jun. 30, 2014
Mar. 31, 2014
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2013
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Alliances Statement [Line Items]                            
Net product sales                 $ 14,045 $ 11,660 $ 12,304      
Alliance revenues                 2,515 4,219 4,081      
Total Revenues $ 4,287 $ 4,069 $ 4,163 $ 4,041 $ 4,258 $ 3,921 $ 3,889 $ 3,811 16,560 15,879 16,385      
Cost of products sold - Amortization of intangible asset                 183 286 858      
Other intangible assets- Non-refundable upfront, milestone and other licensing payments $ 1,419       1,753       1,419 1,753        
Erbitux [Member]                            
Alliances Statement [Line Items]                            
Total Revenues                 501 723 696      
Lilly [Member]                            
Alliances Statement [Line Items]                            
Net product sales                 492 691 696      
Alliance revenues                 9 32        
Total Revenues                 501 723 696      
Cost of products sold - Distribution fees and royalties                 204 287 289      
Cost of products sold - Amortization of intangible asset                 11 37 37      
Cost of products sold - Cost of product supply                 46 69 65      
Royalties                 (70)   $ (30)      
Loss on sale of business                 $ 171          
Other intangible assets- Non-refundable upfront, milestone and other licensing payments         $ 137         $ 137        
Lilly [Member] | Erbitux [Member] | North America [Member]                            
Alliances Statement [Line Items]                            
Distribution fee, percentage of net sales 39.00%               39.00%          
Divestiture non-cash charge                 $ 171          
Royalty rate sales threshold - Minimum $ 165               165     $ 480 $ 650 $ 650
Royalty rate sales threshold - Maximum $ 165               $ 165     $ 480 $ 650 $ 650
Lilly and Merck KGaA [Member] | Erbitux [Member] | Japan [Member]                            
Alliances Statement [Line Items]                            
Percentage share of pre-tax profit/loss received from the net sales of a collaboration partner to be shared further equally with another collaboration partner. 50.00%               50.00%          
Maximum [Member] | Lilly [Member] | Erbitux [Member] | North America [Member]                            
Alliances Statement [Line Items]                            
Royalty rate on net sales                 38.00%          
Minimum [Member] | Lilly [Member] | Erbitux [Member] | North America [Member]                            
Alliances Statement [Line Items]                            
Royalty rate on net sales                 20.00%